ASO Author Reflections: Role of Neoadjuvant Therapy in Surgically Resectable Intrahepatic Cholangiocarcinoma

Affiliations

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hstran@mdanderson.org.

Comment

Meredith C Mason et al. Ann Surg Oncol. 2021 Oct.

. 2021 Oct;28(11):6736-6737.

doi: 10.1245/s10434-020-09541-z. Epub 2021 Jan 15.

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hstran@mdanderson.org.

No abstract available

Comment on

Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience.
Mason MC, Massarweh NN, Tzeng CD, Chiang YJ, Chun YS, Aloia TA, Javle M, Vauthey JN, Tran Cao HS. Mason MC, et al. Ann Surg Oncol. 2021 Oct;28(11):6725-6735. doi: 10.1245/s10434-020-09536-w. Epub 2021 Feb 14. Ann Surg Oncol. 2021. PMID: 33586068

1. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7. - DOI
1. Sur MD, In H, Sharpe SM, et al. Defining the benefit of adjuvant therapy following resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015;22(7):2209–17. - DOI
1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. - DOI
1. Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–28. - DOI
1. Mason MC, Massarweh NN, Tzeng CWD, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-09536-w .